Proactive Investors - Run By Investors For Investors

Aerie Pharmaceuticals in spotlight as FDA judges Rhopressa eye drop

The FDA will decide on Aerie’s Rhopressa eye drop this morning
The stock's trading was halted

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.

Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.

Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.

View full AERI profile View Profile

Related Articles

picture of electric car refuelling
January 25 2017
Enertopia believes the tech it is testing can 'dramatically' alter the current footprint in the lithium industry
picture of platinum
July 10 2017
The miner has notched up another quarter of record production at its Tharisa mine in South Africa
Online shopping
January 23 2017
The referral marketing software provider has been rolling out its Refer-a-Friend platform to a number of new customers over the past few months.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use